瘤相关巨细胞中的JMJD6通过STAT3/IL-10轴调节巨细胞极化和癌症进展
Siyuan Chen1, Manni Wang1, Tianqi Lu1
1Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No.17, Block3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.
Oncogene
|August 11, 2023
概括
含Jumonji域6 (JMJD6) 调节与瘤相关的巨细胞 (TAMs). 抑制JMJD6可以逆转免疫抑制的TAM,增强癌症治疗和免疫检查点阻塞的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 瘤相关巨细胞 (TAMs) 是瘤微环境 (TME) 中的关键免疫细胞.
- 通过免疫抑制,TAM可以促进瘤进展和治疗耐药性.
- 了解TAM调节对于开发有效的癌症疗法至关重要.
研究的目的:
- 为了确定TAM激活和极化的新型调节者.
- 研究JMJD6在TAM介导免疫抑制中的作用.
- 探索向JMJD6在癌症治疗中的治疗潜力.
主要方法:
- 在瘤模型 (路易斯肺癌和B16F10黑色素瘤) 中研究了JMJD6表达.
- 评估JMJD6缺乏对TAM极化和瘤生长的影响.
- 分析了STAT3/IL-10信号在JMJD6介导的M2极化中的参与.
- 评估了JMJD6抑制与免疫检查点阻塞 (ICB) 的组合.
主要成果:
- JMJD6的上调与免疫抑制性TAMs有关.
- 缺乏JMJD6可减少瘤生长,并逆转M2类TAM激活.
- 抑制JMJD6使瘤对ICBs产生敏感性.
- STAT3/IL-10信号通路调解了JMJD6对M2极化的影响.
结论:
- JMJD6是TAM偏振和功能的新型调节器.
- 针对JMJD6/STAT3/IL-10轴提供了一个潜在的战略,以提高ICB的有效性.
- 抑制JMJD6代表了癌症治疗的一个有前途的治疗方法.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K


